EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.87
+3.57%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$43.00
From 52W high−19.61%
Volume5.04M
Market cap$4.26B
P/E (TTM)4.2x
P/S (TTM)—
Div yield—
Key dataNov 5, 2026
Open
$43.00
From 52W high
−19.61%
Volume
5.04M
Market cap
$4.26B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.5x
P/E (TTM)
4.2x
RSI (14)
52.9
MomentumView details →
1D Return
+3.57%
YTD Return
+61.40%
SummaryUpdated Sep 1, 2026
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado. The company went public in March 2021 and focuses on developing innovative small molecule therapies to treat rare musculoskeletal diseases. Edgewise specializes in precision medicine approaches targeting genetically defined muscle disorders, with their lead drug candidate currently in clinical development for treating devastating muscle-wasting diseases including Duchenne muscular dystrophy.
Similar companies
Latest newsMore news →
Edgewise Therapeutics, Inc. reported financial results for the third quarter of 2026.1d agoEdgewise Therapeutics, Inc. said its Phase 3 trial of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy is on track to initiate by year-end 2026.1d agoEdgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%.28d ago